Shanghai Claison Biotechnologic Ltd Company

Shanghai, China

Shanghai Claison Biotechnologic Ltd Company

Shanghai, China
Time filter
Source Type

Zhang M.,Chongqing Cancer Institute | Zhang M.,Guangxi Medical University | Yang T.,Chongqing Cancer Institute | Shi Y.,Chongqing Cancer Institute | And 9 more authors.
Tumor | Year: 2014

Objective: To investigate the efficacy and safety of dendritic cells (DCs)-cytokine-induced killer (CIK) immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: Two hundred seventy-two patients with advanced NSCLC were randomly divided into two groups: study group (n = 136, treated with DCs-CIK immunotherapy combined with chemotherapy) and control group (n = 136, treated with chemotherapy alone). The short-term response was compared between the two groups. The changes of immune function and quality of life before and after treatment in the two groups were compared. The potential efficacy-related factors of DCs-CIK immunotherapy were analyzed, and the adverse reactions were observed to assess its safety. Results: The response rates of study group and the control group were 49.26% and 37.50%, respectively (P > 0.05), and the disease control rates were 68.38% and 54.41%, respectively (P < 0.05). The ratios of CD3+, CD8+ and natural killer (NK) cells in peripheral blood before and after treatment in the two groups had a statistically significant change (P < 0.05). The age, clinical stage and Karnofsky performance status (KPS) score were determined as efficacy-related factors of DCs-CIK immunotherapy. The quality of life was better in the study group than that in the control group (P < 0.05). Only 15 patients in the study group got a low-grade fever after immunotherapy, and no other serious toxicities were found. Conclusion: DCs-CIK immunotherapy combined with chemotherapy can enhance the disease control rate of patients with advanced NSCLC, and improve the immune function and the quality of life without any serious side effects. The age, KPS score and clinical stage may affect the efficacy of DCs-CIK immunotherapy. Copyright © 2014 by TUMOR.

Li Q.-Y.,Chongqing Cancer Institute | Shi Y.,Chongqing Cancer Institute | Huang D.-H.,Chongqing Cancer Institute | Yang T.,Chongqing Cancer Institute | And 12 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015

Objectives: To investigate the prognosis of advanced liver cancer patients treated with CIK-DCs and the mechanism of apoptosis of HEPG 2 cells. Methods: 67 patients were enrolled in the study. Peripheral blood mononuclear cells (PBMCs) were separated, of which adherent PBMCs used granulocyte 2 macrophage colony2 stimulating factor (GM2CSF), tumor necrosis factor 2α (TNF2α), and interleukin 24 (IL24) to induce DCs, which were sensitized with antigen of autologous or exogenous cancer cells to obtain Ag-DCs; suspended PBMCs used interferon 2γ (IFN2γ), IL-2, and CD 3 monoclonal antibody (CD3mAb) respectively, to induce CIK cells. DCs and CIK cells were cultured together. Flow cytometry was used to detect the phenotypes of DCs and CIK cells, and the blood retransfused into patients. Western blot and flow cytometer were used to analyze the growth cycle of HepG 2 cells and the expression of BAX and PCNA. Results: No patients underwent complete remission, 5 obtained partial remission and 29 had stable disease. Of the 31 patients whose lesions could not be evaluated, 17 received effective treatment, showing that the immune response was enhanced. In vitro laboratory experiments revealed that DC-CIK cells markedly affected the growth cycle of HepG 2 cells. Analysis showed that DC-CIK cells enhanced the gene expression of BAX and inhibited the activity of PCNA. Conclusions: Co-cultured DCs and CIK cells inhibit the proliferation and migration of liver cancer cells by down-regulating PCNA and up-regulating BAX. This approach may be an effective method to treat advanced liver cancer. © 2015, E-Century Publishing Corporation. All rights reserved.

Yang T.,Chongqing Cancer Institute | Zhang M.,Chongqing Cancer Institute | Zhang W.-J.,Chongqing Cancer Institute | Wang G.-B.,Chongqing Cancer Institute | And 9 more authors.
Tumor | Year: 2015

Objective: To investigate the effect of secreted cytokines from cytokine-induced killer (CIK) cells on apoptosis of human hepatic cancer stem cells (HCSCs). Methods: The HCSCs were enriched from human hepatic cancer cell line HepG2 by serumfree suspension culture and sphere-forming assay. The expressions of CD90 and CD1 33 of HCSCs were examined by flow cytometry (FCM). The tumorigenicity of HCSCs was detected by nude mouse transplantation tumor experiment. The CIK cells were produced from suspended peripheral blood mononuclear cells (PBMCs) induced by interferon γ (IFNγ), CD3 monoclonal antibody and recombinant human interleukin-2 (rhIL-2). The HCSCs were cultured together with CIK cells at different density in a Transwell chamber and cultured separately by the membrane of the Transwell chamber for 24 and 48 h, respectively. The apoptosis of HCSCs, which were cultured with CIK cells for 24 and 48 h, was analyzed by FCM. The expression levels of caspase-3 mRNA and protein were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively. Results: The result of FCM revealed that the stem cell markers CD90 and CD1 33 were highly expressed on the surface of HCSCs. The nude mouse transplantation tumor experiment showed that HCSCs possessed a high ability of tumorigenicity. The apoptosis of HCSCs could be significantly induced by secreted cytokines from CIK cells as compared with that of the control group (P < 0.01). The caspase-3 mRNA and protein expression levels were significantly up-regulated in HCSCs induced by secreted cytokines from CIK cells. Conclusion: The secreted cytokines from CIK cells can induce apoptosis of HCSCs, and this effect may be related to upregulation of caspase-3 expression. Copyright © 2015 by TUMOR All rights reserved.

Yang T.,Chongqing Tumor Institute | Shao J.-H.,Chongqing Tumor Institute | Li Q.-Y.,Chongqing Tumor Institute | Yu H.-Q.,Chongqing Tumor Institute | And 4 more authors.
Tumor | Year: 2010

Objective: To evaluate the therapeutic effect of cytokine induced killer (CIK) cells in combination with dendritic cells (DCs) on advanced solid tumor. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 110 patients with advanced solid tumor. The adherent cells were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF) -alpha, and interleukin-4 (IL-4) to induce DCs. The DCs were sensitized with antigens of autologous tumor cells or extrinsic tumor cell lines to produce Ag-DCs. Suspending cells were cultured with interferon-γ (IFN-γ), interleukin-2 (IL-2), and CD3 monoclonal antibody (CD3 mAb) to prepare CIK cells. Then, the CIK cells were co-cultured with DCs. The phenotype of DCs and CIK cells were analysed using flow cytometry. The autologous CIK cells and DCs were transfused into the patients who had advanced solid tumor. Results: In the 42 patients who were eligible for evaluation, 2 achieved complete remission (CR),9 partial remission (PR) and 15 stable disease (SD). In the 37 patients who were not eligible for evaluation, 25 had efficient response. The immune function was improved and the level of tumor markers were altered significantly compared with those before treatment. Conclusion: CIK cells in combination with DCs treatment is safe and effective in the treatment of advanced malignant solid tumors and has a better application foreground in clinic.

Loading Shanghai Claison Biotechnologic Ltd Company collaborators
Loading Shanghai Claison Biotechnologic Ltd Company collaborators